Open Access

Fatal Kikuchi-like lymphadenitis associated with connective tissue disease: a report of two cases and review of the literature

SpringerPlus20154:167

https://doi.org/10.1186/s40064-015-0925-7

Received: 12 March 2015

Accepted: 13 March 2015

Published: 8 April 2015

Abstract

Introduction

Kikuchi-Fujimoto disease, is usually a benign self-limiting disease which typically affects young females under the age of 30 years and resolves without treatment within six months. However, when it occurs in the context of connective tissue disease, particularly systemic lupus erythematosus (SLE), it is usually associated with a flare-up of the patient’s symptoms, requiring treatment, and can lead to severe, potentially life-threatening sequelae.

Case description

Here, we report and compare two cases of unclassifiable connective tissue disease who developed a Kikuchi-like lymphadenitis and sepsis-like clinical syndrome, including disseminated intravascular coagulation, which proved rapidly fatal.

Discussion and evaluation

In our review of the literature, we found 55 cases of Kikuchi-Fujimoto disease occurring in the context of definite connective tissue disease, 50 of which were associated with SLE. Of the 55 cases, 22 (40%) had simultaneous onset with, 19 (35%) predated the onset of and 14 (25%) developed after the associated connective tissue disease. Life-threatening autoimmune sequelae were reported in 8 cases, 2 of which were fatal. The aetiology of the association remains unknown.

Conclusion

Kikuchi-Fujimoto disease is a histopathological diagnosis, and although the classical form appears to represent a distinct entity, it is unclear whether it is always the same entity, regardless of the context in which it occurs, or whether it represents a histological pattern with a variety of possible causes. In any case, the possibility of auto-immune sequelae in patients with known autoimmune disease should always be considered if these patients present with a sepsis-like clinical syndrome and no infective source is identified.

Keywords

Kikuchi-Fujimoto diseaseNecrotising lymphadenitisConnective tissue diseaseSystemic lupus erythematosusLymphadenopathy

Introduction

Kikuchi-Fujimoto disease, also known as histiocytic necrotising lymphadenitis, is a benign self-limiting disease which typically affects young females under the age of 30 years and resolves without treatment within six months. The disease was originally described in Japan in 1972 and is known to be more common in Asian populations. The aetiology is unknown, and knowledge about the condition is derived mostly from case reports. Although both viral and autoimmune aetiologies have been proposed, there is no convincing evidence linking Kikuchi-Fujimoto disease to either of these aetiologies. Although the disease course is normally self-limiting, fatal cases are known to occur, with a reported fatality rate of 2.1% (Kucukardali et al. 2007; Chan et al. 1989). An association between a Kikuchi-like lymphadenitis and autoimmune disease, particularly systemic lupus erythematosus (SLE), has been noted. The lymphadenitis occurring in this context can produce a sepsis-like clinical syndrome which is potentially life-threatening. Here, we compare and contrast two cases of patients with longstanding connective tissue disease which proved hard to classify, both of whom developed a fatal Kikuchi-like lymphadenitis.

Case 1

This was a case of a 57 year old woman with a long history of connective tissue disease. She suffered from Raynaud’s phenomenon for 35 years, and, at the age of 29, a biopsy of nodular lesions affecting the elbows, ankles and hands revealed rheumatoid nodules/granuloma annulare. She subsequently developed widespread inflammatory arthritis. She also suffered from psoriasis, and psoriatic arthropathy was the preferred diagnosis for a period of time. However, she had an autoantibody profile which included a positive ANF with a speckled pattern, positive anti-La and positive RNP, and mixed connective tissue disease was eventually considered to be the most likely diagnosis. Rheumatoid factor was negative. She had multiple drug allergies, including to numerous antibiotics, and declined systemic therapy. Her arthritis was treated with steroid injections.

She was admitted to the Medical Unit with a few days history of fever, right flank pain and mild urinary frequency. She had been having recurrent urinary tract infections over the previous three months and was diagnosed with pyelonephritis. She was treated with teicoplanin and gentamicin and her symptoms improved. However, blood cultures were negative and a renal ultrasound scan was normal. She was discharged home, but was readmitted three days later with a recurrence of her symptoms. On admission she had a fever of 38-40°C and an erythematous rash on her trunk, but physical examination was otherwise unremarkable. Her CRP increased from 17 on admission to 72 the following morning. Her white cell count was not elevated and a chest X-ray showed no obvious consolidation. Her antibiotics were restarted. Three days later, she rapidly became breathless, hypotensive, poorly perfused and tachycardic. Blood analyses revealed significant biochemical and haematological derangement including raised phosphate and creatinine levels, low albumin, a neutrophilia and thrombocytopaenia/disseminated intravascular coagulation (DIC) (Table 1). A diagnosis of septic shock was made. During transfer to intensive care, she suffered a cardiac arrest and failed to respond to resuscitation attempts.
Table 1

Comparison of the biochemical and haematological parameters of both cases following the onset of their deterioration into thrombocytopenia/DIC

 

Case 1

Case 2

Normal range

Sodium (mmol/l)

131

138

136-144

Potassium (mmol/l)

6.3

5.2

3.8-5.0

Chloride (mmol/l)

104

110

95-105

Bicarbonate (mmol/l)

6

7

24-32

Urea (mmol/l)

8.1

6.9

2.5-6.0

Creatinine (μmol/l)

234

84

45-100

Estimated GFR (ml/min/1.73 m 2 )

20

>60

>90*

Lactate (mmol/l)

NA

1.32

0.63-2.44

Bilirubin (μmol/l)

7

14

<21

Alkaline Phosphatase (units/l)

101

86

30-90

ALT (units/l)

399

1514

5-40

Albumin (g/l)

11

15

36-52

Calcium (mmol/l)

1.54 2.12 adjusted

2.13 2.63 adjusted

2.10-2.60

Magnesium (mmol/l)

1.16

1.01

0.7-1.0

Phosphate (mmol/l)

3.97

1.93

0.80-1.50

C-reactive protein (mg/l)

72

18

0-9

Troponin I (μg/l)

4.66

NA

0.01-0.04

Haemoglobin (g/l)

179

88

118-148

Haematocrit

0.550

0.261

0.36-0.44

Platelets (10 9 /l)

27

13

150-400

White cell count (10 9 /l)

22.8

4.1

4.0-11.0

Neutrophils (10 9 /l)

17.7

1.4

2.0-7.5

Prothrombin time (seconds)

Too prolonged to quantify

46

10-14

Partial prothrombin time (seconds)

Too prolonged to quantify.

91

26-36

Fibrinogen (g/l)

1.2

0.6

1.5-4.0

D-Dimer (ng/ml)

34761

NA

<250

*Although this is the normal range, eGFR is not accurate at near-normal levels of GFR and many laboratories, including ours, do not quantify the eGFR if it is above 60.

Post mortem examination was unremarkable, and no infective source was identified. Histology of lymph nodes harvested from the neck bilaterally, peritonsillar area, tracheobronchial region, axillae, groins and small bowel mesentery, as well as the spleen, showed similar features. There were large areas of interfollicular necrotising inflammation with a prominent histiocytic population and admixed lymphocytic debris, but no neutrophils (Figure 1). Immunohistochemistry revealed that the interfollicular/ paracortical areas were populated predominantly by cytotoxic/CD8-positive T-cells. The cause of death was given as mixed connective tissue disease-associated necrotising lymphadenitis and splenitis.
Figure 1

Histology of lymph nodes and spleen from Case 1. A-B: Low (x100) and high (x400) power views of peritonsillar lymph node. C-D: Low (x100) and high (x400) power views of spleen.

Case 2

This 55 year old woman had a complex history of connective tissue disease; features of Sjogren’s syndrome and SLE were present and she also had small fibre neuropathy and asthma. She had positive anti-Ro and anti-La antibodies. She had been suffering from sciatica and was electively admitted for a decompression laminectomy of L4/L5 to alleviate her symptoms. She had an uneventful recovery and was discharged home.

10 days later, following significant sun exposure, she was re-admitted with pyrexia (40°C), dizziness, loss of balance, decreased hearing, diarrhoea, vomiting and a non-blanching rash over the upper arms and thighs. A clinical diagnosis of sepsis was made, and she was started on broad-spectrum antibiotics. No infective source was found. Stool cultures showed no evidence of Clostridium difficile and the blood and urine cultures were negative. An MRI of the lumbosacral spine showed features most in keeping with a surgical seroma. Despite treatment, her condition deteriorated over the next three days and she was admitted to ITU with lactic acidosis, haemodynamic collapse, and thrombocytopenia/DIC. Despite organ support, she died three days after her admission.

Post mortem examination was unremarkable and no infective source was identified. The cervical, carinal and para-aortic lymph nodes showed paracortical necrotising inflammation with a prominent histiocytic population admixed with lymphocytes and some karryorrhectic debris, but no neutrophils (Figure 2A and B). The lymphocytes were predominantly cytotoxic/CD8-positive T-cells. The lymph nodes also showed vascular thrombosis (Figure 2C and D), and one of the para-aortic lymph nodes was extensively infarcted. Focal areas of haemophagocytosis were identified (Figure 3). The cause of death was given as SLE-associated Kikuchi disease.
Figure 2

Histology of lymph nodes from Case 2. A-B Low (x100) and high (x400) power views of para-aortic lymph node. C. High power (x400) view of same lymph node showing medium vessel thrombosis. D. Low power (x100) view of same lymph node showing large vessel thrombosis.

Figure 3

High power (x400) view of para-aortic lymph node showing a focus of haemophagocytosis.

Discussion

The etiology of Kikuchi-Fujimoto disease remains unclear. Suggested causative agents which have been isolated from lymph nodes exhibiting the disease include Ebstein-Barr virus, HIV, human T-cell leukaemia virus type 1, human herpesvirus type 6 and 8, hepatitis B virus, parvovirus B19, herpes simplex, varicella zoster, cytomegalovirus, Toxoplasma gondii, Brucella, Yersinia enterolitica and parainfluenza virus (Kucukardali et al. 2007; Bosch et al. 2004; Bosch and Guilabert 2006). It has been proposed that these agents activate CD8-positive T cells leading to T-cell proliferation and apoptosis mediated by the Fas and perforin pathways. Engulfment of the apoptotic debris by macrophages would then give rise to the typical histological features. However, there is no conclusive evidence that any of these agents are the cause of Kikuchi-Fujimoto disease. In many cases, no infectious agent is found (Kucukardali et al. 2007; Bosch et al. 2004; Bosch and Guilabert 2006).

The other main proposed aetiology is autoimmune, based on the observation that a Kikuchi-like lymphadenitis occurs in the context of autoimmune disease, particularly SLE. The pathogenesis of SLE is believed to be related to defective processing of apoptotic debris, resulting in components of the debris being mistakenly presented to the immune system. Situations in which apoptosis is increased, such as Kikuchi-Fujimoto disease, could conceivably accelerate the generation of autoantibodies and increase the levels of autoantigens present, precipitating a flare-up of the disease (Santana et al. 2005). It has been suggested that the trigger may be an autoimmune response to an epithelial antigen, such as those seen in cutaneous SLE reactions (Gordon et al. 2009). Electron microscopy has shown that the histiocytes, activated lymphocytes and endothelial cells in the affected lymph nodes of Kikuchi-Fujimoto disease contain tubuloreticular structures similar to those seen in endothelial cells and lymphocytes of patients with SLE (Imamura et al. 1982). The significance of this observation is uncertain, although it hints at a common pathogenesis. Some authors consider it to be supporting evidence for a hyperimmune response of viral aetiology (Gionanlis et al. 2009). It has been suggested that Kikuchi-Fujimoto disease lies on the same disease spectrum as SLE, representing a milder form of the disease (Gionanlis et al. 2009). There is one report of two twin sisters who were human-leucocyte antigen-identical, each of whom developed Kikuchi-Fujimoto disease 10 years apart. This observation hints at the possibility of a genetic predisposition. However, neither of the sisters developed SLE or any other autoimmune sequelae (Amir et al. 2002).

Kikuchi-Fujimoto disease is a histopathological diagnosis and is probably under-recognised. It is characterised by focal cortical and paracortical necrosis with marked karyorrhexis and an infiltrate of crescentic histiocytes and plasmacytoid monocytes which lacks neutrophils. The appearances of lupus lymphadenitis can be similar. Additional features seen in lupus lymphadenitis include neutrophils, plasma cells and haematoxylin bodies, but distinction between the two entities is not always possible. Many authors recommend long-term follow-up of patients with Kikuchi-Fujimoto disease to watch for the development of SLE (Santana et al. 2005; Bosch et al. 2004; Bosch and Guilabert 2006). In the analysis of 244 reported cases of Kikuchi-Fujimoto disease by Kucukardali et al., 56 (23%) were associated non-infectious inflammatory diseases of which 32 (13%) were associated with SLE (Kucukardali et al. 2007).

In the two cases presented here, the presence of Kikuchi-like lymphadenitis in the context of connective tissue disease produced a sepsis-like clinical picture, with thrombocytopenia and DIC, which proved fatal. The differential diagnosis included true sepsis, which was the working diagnosis in both cases, and this posed a difficult therapeutic dilemma given that the true diagnoses in these cases are extremely rare, whereas sepsis is common. In our review of the literature, we found reports of 8 cases of similar life-threatening autoimmune sequelae, 2 of which were fatal, 1 of which eventually resulted in a persistent vegetative state, and 5 of which were successfully treated with pulse corticosteroids with or without cyclophosphamide (Tables 2, 3 and 4). Commencement of such therapy in these cases would have required definitive exclusion of an infective cause, for which there was not enough time due to the rapidity of the clinical decline. Tables 1 and 5 compare the clinical, biochemical and haematological features of the two cases. Both had connective tissue disease which was difficult to classify, although it was eventually felt that case 2 probably had SLE. The autoantibody profiles were different, but both were non-specific. In case 1, the necrotising lymphadenitis also involved the spleen. This is an extremely rare finding in Kikuchi lymphadenitis, and was a feature of one of the two previously reported fatal cases of SLE-associated Kikuchi lymphadenitis (Quintas-Cardama et al. 2003).
Table 2

Clinical characteristics of previously reported cases of Kikuchi-Fujimoto disease occurring simultaneously with connective tissue disease

Necrotising lymphadenitis occurring simultaneously with connective tissue disease

Country and reference

Age and gender

Connective tissue disease

Autoantibodies

Outcome

Greece (Gionanlis et al. 2009)

23 year old Female

SLE

ANA, anti-dsDNA, Anti-Ro, Anti-La, anti-RNP

Renal failure.TTP. Responded to immunosuppression + rituximab.

USA (Smith and Petri 2013)

27 year old Female

SLE

ANA, anti dsDNA, anticardiolipin IgG and IgM, anti-Smith, anti-Ro, anti-La.

Developed lupus nephritis. Condition stable.

Japan (Aota et al. 2009)

36 year old Male

SLE

ANA

Lymphadenitis resolved with corticosteroid therapy. Developed lupus nephritis. Condition stable at 4 month follow up.

France (Gallien et al. 2008)

47 year old Male

SLE

ANA, anti-dsDNA

Lymphadenitis resolved with corticosteroid therapy.

France (Frikha et al. 2008)

14 year old Female

SLE

ANA, anti-RNP, anti-Ro

Lymphadenitis resolved with corticosteroid therapy.

France (Frikha et al. 2008)

23 year old Female

SLE

ANA, anti-dsDNA, anti-Sm, anti-RNP, anti-Ro, anti-La.

Lymphadenitis resolved with corticosteroid therapy.

Germany (Hoffmann et al. 1991)

37 year old Male

SLE

HHV-6

No life-threatening sequelae.

England (Shusang et al. 2008)

20 year old Female

SLE Had 3 year history of autoimmune hepatitis

ANA (at onset of autoimmune hepatitis) Anti-Ro, anticardiolipin (at onset of SLE)

Lymphadenitis resolved with corticosteroid therapy.

Turkey (Yilmaz et al. 2006)

53 year old Female

SLE

ANA

No life-threatening sequelae.

Singapore (Chua et al. 1996)

9 year old Female

SLE with erythema multiforme

ANA, anti-dsDNA

No life-threatening sequelae.

USA (Eisner et al. 1996)

Young male

SLE

ANA

Concurrent lupus nephritis. Complete remission with corticosteroid therapy and cyclophosphamide.

France (Leyral et al. 2005)

26 year old Female

SLE

ANA, anti-dsDNA

Haemophagocytic syndrome with EBV infection. Complete remission with corticosteroids.

Romania (Tanasescu et al. 2003)

17 year old Female

SLE and autoimmune hepatitis

Anti-Sm

Complete remission with corticosteroid therapy

Brazil (Santana et al. 2005)

20 year old Female

SLE

ANA, anti-Ro, anticardiolipin

Lymphadenitis resolved with corticosteroid therapy.

Spain (Jimenez Saenz et al. 2001)

30 year old Female

SLE

ANA, anti-dsDNA, anti-RNP, anti-scl 70

Complete remission with corticosteroid therapy.

USA (Mahajan et al. 2007)

56 year old Female

SLE

ANA, anti-dsDNA

Partial improvement with hydroxychloroquine, followed by complete remission.

USA (Gordon et al. 2009)

33 year old Male

SLE

ANA, anti-Smith, anti-RNP, anti-Ro.

Complete remission with corticosteroid therapy.

Germany (Cramer et al. 2010)

33 year old Male

SLE

ANA, anti-dsDNA

Clinical improvement with corticosteroid and mycophenolate therapy.

USA (Quintas-Cardama et al. 2003)

38 year old Female

SLE

ANA

Severe auto-immune-related clinical sequelae and cardiogenic shock. Patient died despite pulse corticosteroid and cyclophosphamide therapy.

Spain (Sopena et al. 2012)

27 year old Female

SLE

ANA

Good response to therapy.

Spain (Diez-Morrondo et al. 2012)

22 year old Female

SLE

ANA

Good response to hydroxychloroquine.

Thailand (Kampitak 2008)

50 year old Male

SLE

ANA

Developed haemophagocytic syndrome and severe hospital acquired pneumonia and septic shock. Patient died.

Table 3

Clinical characteristics of reported cases of Kikuchi-Fujimoto disease occurring after the onset of connective tissue disease

Connective tissue disease predating necrotising lymphadenitis

Country and reference

Age and gender

Connective tissue disease

Autoantibodies

Outcome

Canada (Silver et al. 2004)

43 year old Female

Discoid lupus erythematosus for 10 years

None

Recovered without treatment

India (Londhey et al. 2010)

39 year old Female

SLE for 2 years (not initially diagnosed)

ANA and anti-dsDNA

No life-threatening sequelae. Responded to corticosteroids and hydroxychloroquine. Asymptomatic at 1 year follow-up.

Canada (Pace-Asciak et al. 2008)

35 year old Female

SLE (duration not stated)

NA

Lymphadenitis resolved with conservative management.

France (Frikha et al. 2008)

30 year old Female

Mixed connective tissue disease for 8 years

ANA, anticardiolipin

Lymphadenitis resolved with corticosteroid therapy.

Taiwan (Chen and Lan 1998)

4 cases All female Ages 21–35 years old

SLE for 8 days to 2 years

Ribosomal-P antibodies (1 case) RNP (1 case) None (2 cases)

No life-threatening sequelae

France (Abraham et al. 2011)

35 year old Female

Overlap syndrome for 12 years

Antiphospholipid antibodies

Lymphadenitis resolved with corticosteroid therapy.

Sabah (Bachi 2002)

27 year old Female

SLE – systemic symptoms for 2 months

ANA, anti-Ro, anti-La at onset of lymphadenitis

Complete remission with corticosteroid therapy.

Japan (Wano et al. 2000)

37 year old Female

SLE for 2 years

NA

Haemophagocytic syndrome. Complete remission with corticosteroid pulse therapy.

India (Londhey et al. 2010)

39 year old Female

Onset of connective tissue disease for 4 years. Lymphadenitis first appeared after 2 years. SLE diagnosis established later.

ANA, anti-dsDNA.

Complete remission with corticosteroid therapy.

Spain (Sopena et al. 2012)

2 cases 22 and 32 years old Both Female

Both SLE. Onset not stated.

ANA only (1 case) ANA, anticardiolipin, anti-Ro, RNP (1 case)

Good response to therapy

Italy (Ruaro et al. 2014)

19 year old Male

SLE, onset 2–3 months prior to diagnosis of Kikuchi lymphadenitis

ANA only

Initial good response to therapy, single episode of relapse 2 years after initial onset, subsequently symptom free on corticosteroid and methotrexate therapy.

Table 4

Clinical characteristics of reported cases of Kikuchi-Fujimoto disease occurring before the onset of connective tissue disease

Necrotising lymphadenitis predating connective tissue disease

Country and reference

Age, gender

Connective tissue disease

Autoantibodies

Outcome

Saudi Arabia (el-Ramahi et al. 1994)

22 year old Female

SLE after 5 months

ANA, anti-Sm, anti-dsDNA, anti-Ro, anti-La.

Lymphadenitis resolved with corticosteroid therapy.

Saudi Arabia (el-Ramahi et al. 1994)

34 year old Female

SLE after several months

ANA, anti dsDNA, anti-Sm

Not stated.

Thailand (Sanpavat et al. 2006)

28 year old Female

SLE after 44 weeks

ANA, anti-dsDNA

Lymphadenitis resolved with corticosteroid therapy.

Spain (Paradela et al. 2008)

17 year old Female

SLE onset after 9 months

ANA, anti-dsDNA

No life-threatening sequelae.

Australia (Goldblatt et al. 2008)

22 year old Female

SLE after 3 months

ANA, anti-Ro, anti-Sm at onset of SLE.

Complete remission with corticosteroid therapy.

Australia (Goldblatt et al. 2008)

39 year old Female

SLE after 14 months

ANA, anti-dsDNA, anti-Ro, anti-Sm, anticardiolipin.

Complete remission with immunosuppression.

Australia (Goldblatt et al. 2008)

31 year old Female

SLE after 6 months

ANA, anti-dsDNA, anti-Ro at onset of SLE

Treated with corticosteroids, azathioprine and hydroxychloroquine. 2 years later, developed meningoencephalitis leading to a persistent neuro-vegetative state.

Australia (Goldblatt et al. 2008)

14 year old Female

SLE after a few days

Anti-dsDNA at onset of SLE.

Complex clinical course with lupus nephritis. Eventual remission with B-cell depletion therapy.

Spain (Alijotas-Reig et al. 2008)

31 year old Female

SLE after years. Lymphadenitis was pregnancy-associated and did not recur at onset of SLE.

ANA, anti-RNP, borderline anti-dsDNA at onset of SLE.

Persisting arthralgias and asthenia.

Japan (Ogata et al. 2010)

7 year old Male

Mixed connective tissue disease after 2 months

Weak anti-Ro, anti-La, anti-Sm, antiphospholipid and anti-RNP at onset of connective tissue disease

Complete remission with corticosteroid therapy.

Japan (Ogata et al. 2010)

6 year old Female

SLE after 2 years

ANA, anti-dsDNA, anti-Sm, anti-RNP at onset of SLE.

Complete remission with corticosteroid and cyclophosphamide pulse therapy.

Spain (Sopena et al. 2012)

4 cases 27–32 years old All Female

Sjogren syndrome (2 cases) SLE (1 case) SLE-like (1 case)

ANA, anti-Ro (Sjogren cases) ANA only (SLE-like case)

1 case had a near-fatal clinical course, treated with intravenous immunoglobulins. 2 of the remaining cases had relapses of lymphadenitis.

USA (Zuo et al. 2012)

23 year old Female

SLE after three months

ANA and rheumatoid factor at onset of lymphadenitis ANA, anti-Ro, anti-La, anti-dsDNA, anti-Smith, anti-RNP at onset of SLE

Not stated.

India (Patra and Bhattacharya 2013)

30 year old Female

SLE after 2 years

ANA, anti-dsDNA at onset of SLE

Complete remission with immunosuppression.

Italy (Di Lernia et al. 2013)

42 year old Female

Cutanerous lupus after two months

Anti-Ro, ENA at onset of cutaneous lupus

Complete remission with prednisolone and hydroxychloroquine.

India (Patra and Bhattacharya 2014)

30 year old Female

SLE after two years

ANA and anti-dsDNA at onset of SLE

Complete remission with immunosuppression

Table 5

Comparison of the main clinical and pathological features of the two cases (DIC = disseminated intravascular coagulation; SLE = systemic lupus erythematosus)

 

Case 1

Case 2

Age and Gender

57 year old female.

55 year old female.

Past Medical History

Mixed connective tissue disease - including arthritis, Raynaud’s phenomenon and rheumatoid nodules/granuloma annulare. Psoriasis. Multiple drug allergies.

SLE/ Sjogren’s syndrome. Small fibre neuropathy. Asthma.

Clinical presentation

No sun exposure. Pyrexia (38-40°C), flank pain, urinary frequency, erythematous rash on trunk. Deteriorated into sepsis-like clinical picture.

Sun exposure. Pyrexia (40°C), non-blanching rash over upper arms and thighs, sepsis-like clinical picture.

Autoantibodies

ANA with speckled pattern, anti-La and RNP.

Anti-Ro and Anti-La.

Thrombocytopenia/DIC

Yes

Yes

Acidosis

Yes

Yes

Lymph node histology

Necrotising lymphadenitis.

Necrotising lymphadenitis.

Blood vessel thrombosis

No

Yes

Spleen involvement

Yes

No

Case 2 had a number of features which are more closely associated with SLE. Firstly, there was a history of sun exposure. In this context, it is noteworthy that anti-Ro and anti-La antibodies, which were positive in this patient, are particularly associated with photosensitivity (Sontheimer et al. 1979). One model of the pathogenesis of photosensitivity in SLE proposes that exposure of keratinocytes to ultraviolet light increases the surface expression of Ro antigen. Anti-Ro antibodies would then bind these receptors and precipitate a cutaneous reaction which then begets a systemic reaction (Furukawa et al. 1999). It is tempting to speculate that such a mechanism may have triggered the final illness in Case 2, but this cannot be known for certain. This case showed vascular thrombosis in the affected lymph nodes, a feature which is seen in SLE.

Case 2 also showed focal evidence of haemophagocytosis in the lymph nodes. This was an interesting observation, but one whose significance is uncertain. Haemophagocytic syndrome has been previously described in cases of Kikuchi-Fujimoto disease occurring in the context of SLE (Wano et al. 2000; Kampitak 2008; Leyral et al. 2005). However, there was no conclusive evidence for the presence of the haemophagocytic syndrome in this case.

In our review of the literature, we found 55 cases of Kikuchi-Fujimoto disease occurring in the context of definite connective tissue disease, 50 of which were associated with SLE. Of the 55 cases, 22 (40%) had simultaneous onset with, 19 (35%) predated the onset of and 14 (25%) developed after the associated connective tissue disease. The association was usually associated with a flare-up of disease activity, the severity of which varied. Life-threatening autoimmune sequelae, as discussed above, were reported in 8 cases, 2 of which resulted in fatalities (Tables 2, 3 and 4).

The appearance of autoantibodies was associated with the onset of the connective tissue disease rather than the lymphadenitis in all but 2 cases. Of the two cases in which autoantibodies were linked to the onset of lymphadenitis, one developed further antibodies following the onset of SLE (Bachi 2002; Zuo et al. 2012). There were several reported cases of Kikuchi-Fujimoto disease occurring in the context of skin manifestations, which provided interesting but conflicting insights into the relationship between the lymphadenitis and the appearance of autoantibodies (Prignano et al. 2012; Paradela et al. 2008; Yilmaz et al. 2006; Mootsikapun et al. 2002; Silver et al. 2004). On the one hand, two of these cases had positive ANA antibodies, but a diagnosis of SLE was excluded (Prignano et al. 2012; Yilmaz et al. 2006). On the other hand, one was a case of discoid lupus who developed Kikuchi-Fujimoto disease without developing autoantibodies (Silver et al. 2004), and another was a case which went on to develop SLE, with auto-antibodies appearing only at the onset of SLE (Paradela et al. 2008). As an aside, the authors of this report made the observation that cases of cutaneous manifestations of Kikuchi-Fujimoto disease which progressed to SLE were associated with interface dermatitis, and suggested that this feature may be a predictor of progression. In one case, the lymphadenitis preceded the appearance of cutaneous lupus, with autoantibodies appearing only at the onset of cutaneous lupus (Vassilakopoulos et al. 2010). Autoantibodies have also rarely been reported to appear in the classical self-limiting form of Kikuchi’s lymphadenitis, resolving when the lymphadenitis resolves (Vassilakopoulos et al. 2010). Finally, one intriguing report described a case of Kikuchi-Fujimoto disease and systemic SLE-like symptoms without any autoantibodies. The symptoms resolved spontaneously within 3 months without treatment, and did not recur (Mootsikapun et al. 2002). Overall, although Kikuchi-like lymphadenitis can rarely be associated with the appearance of autoantibodies, these cases would appear to be the exception rather than the rule. This observation would argue against a straightforward autoimmune aetiology.

In conclusion, Kikuchi-Fujimoto disease occurring in the context of connective tissue disease does not usually take the benign self-limiting course which typifies the classical form of the disease. It is usually associated with a flare-up of the connective tissue disease requiring treatment, and can lead to severe, potentially life-threatening sequelae. The aetiology of this effect is unclear, but clinically it can mimic sepsis. In this context, the possibility of auto-immune sequelae in patients with known autoimmune disease should always be considered if no infective source is identified. Although the classical self-limiting form of Kikuchi-Fujimoto disease appears to represent a distinct clinical and pathological disease, it is unclear whether it is always the same entity, regardless of the context in which it occurs, or whether it represents a histological pattern with a variety of possible causes.

Declarations

Authors’ Affiliations

(1)
Department of Pathology, Raigmore Hospital
(2)
Department of Pathology, Aberdeen Royal Infirmary
(3)
Division of Applied Medicine, School of Medicine and Dentistry, University of Aberdeen

References

  1. Abraham M, Lazareth I, Bonardel G, Albiges L, Dechaud C, Marini V, Michon-Pasturel U, Molinier V, Priollet P (2011) [Kikuchi disease and lupus: case report, literature review and FDG PET/CT interest]. J Mal Vasc 36(4):274–9, doi:10.1016/j.jmv.2011.05.004View ArticleGoogle Scholar
  2. Alijotas-Reig J, Casellas-Caro M, Ferrer-Oliveras R, Cabero-Roura L, Vilardell-Tarres M (2008) Recurrent Kikuchi-Fujimoto disease during pregnancy: report of case evolving into systemic lupus erythematosus and review of published work. J Obstet Gynaecol Res 34(4 Pt 2):595–8, doi:10.1111/j.1447-0756.2008.00727.xView ArticleGoogle Scholar
  3. Amir AR, Amr SS, Sheikh SS (2002) Kikuchi-Fujimoto’s disease: report of familial occurrence in two human leucocyte antigen-identical non-twin sisters. J Intern Med 252(1):79–83, doi:1004View ArticleGoogle Scholar
  4. Aota N, Hirahara K, Kano Y, Fukuoka T, Yamada A, Shiohara T (2009) Systemic lupus erythematosus presenting with Kikuchi-Fujimoto’s disease as a long-term sequela of drug-induced hypersensitivity syndrome. A possible role of Epstein-Barr virus reactivation. Dermatology 218(3):275–7, doi:10.1159/000187619View ArticleGoogle Scholar
  5. Bachi R (2002) Kikuchi disease in a connective tissue disorder. Med J Malaysia 57(3):357–60Google Scholar
  6. Bosch X, Guilabert A (2006) Kikuchi-Fujimoto disease. Orphanet J Rare Dis 1:18, doi:10.1186/1750-1172-1-18View ArticleGoogle Scholar
  7. Bosch X, Guilabert A, Miquel R, Campo E (2004) Enigmatic Kikuchi-Fujimoto disease: a comprehensive review. Am J Clin Pathol 122(1):141–52, doi:10.1309/YF08-1L4T-KYWV-YVPQView ArticleGoogle Scholar
  8. Chan JK, Wong KC, Ng CS (1989) A fatal case of multicentric Kikuchi’s histiocytic necrotizing lymphadenitis. Cancer 63(9):1856–62View ArticleGoogle Scholar
  9. Chen YH, Lan JL (1998) Kikuchi disease in systemic lupus erythematosus: clinical features and literature review. J Microbiol Immunol Infect 31(3):187–92Google Scholar
  10. Chua SH, Giam YC, Sim CS (1996) Systemic lupus erythematosus with erythema multiforme-like lesions and histiocytic necrotizing lymphadenitis–a case report. Ann Acad Med Singapore 25(4):599–601Google Scholar
  11. Cramer J, Schmiedel S, Alegre NG, Schafer H, Burchard GD, Merz H (2010) Necrotizing lymphadenitis: Kikuchi--Fujimoto disease alias lupus lymphadenitis? LUPUS 19(1):89–92, doi:10.1177/0961203309345793View ArticleGoogle Scholar
  12. Di Lernia V, Bajocchi G, Piana S (2013) Subacute cutaneous lupus erythematosus onset preceded by Kikuchi-Fujimoto disease. Dermatol Pract Concept 4(1):47–9, doi:10.5826/dpc.0401a06 dp0401a06Google Scholar
  13. Diez-Morrondo C, Pantoja-Zarza L, Manjon-Haces JA (2012) Kikuchi Fujimoto’s disease appearing as systemic lupus erythematosus. Reumatol Clin 8(3):153–5, doi:10.1016/j.reuma.2011.09.009Google Scholar
  14. Eisner MD, Amory J, Mullaney B, Tierney L Jr, Browner WS (1996) Necrotizing lymphadenitis associated with systemic lupus erythematosus. Semin Arthritis Rheum 26(1):477–82, doi:S0049-0172(96)80028-XView ArticleGoogle Scholar
  15. el-Ramahi KM, Karrar A, Ali MA (1994) Kikuchi disease and its association with systemic lupus erythematosus. LUPUS 3(5):409–11View ArticleGoogle Scholar
  16. Frikha F, Marzouk S, Frigui M, Jallouli M, Kechaou M, Kaddour N, Boudawara T, Jlidi R, Bahloul Z (2008) [Kikuchi-Fujimoto’s disease and connective tissue disease: a report of three cases]. Rev Med Interne 29(2):129–34, doi:10.1016/j.revmed.2007.07.012View ArticleGoogle Scholar
  17. Furukawa F, Itoh T, Wakita H, Yagi H, Tokura Y, Norris DA, Tagikawa M (1999) Keratinocytes from patients with lupus erythematosus show enhanced cytotoxicity to ultraviolet radiation and to antibody-mediated cytotoxicity. Clin Exp Immunol 118(1):164–70, doi:cei1026View ArticleGoogle Scholar
  18. Gallien S, Lagrange-Xelot M, Crabol Y, Briere J, Galicier L, Molina JM (2008) Med Mal Infect 38(7):392–5, doi:10.1016/j.medmal.2008.03.010View ArticleGoogle Scholar
  19. Gionanlis L, Katsounaros M, Bamihas G, Fragidis S, Veneti P, Sombolos K (2009) Kikuchi-Fujimoto disease and systemic lupus erythematosus: the EBV connection? Ren Fail 31(2):144–8, doi:10.1080/08860220802595518View ArticleGoogle Scholar
  20. Goldblatt F, Andrews J, Russell A, Isenberg D (2008) Association of Kikuchi-Fujimoto’s disease with SLE. Rheumatology (Oxford) 47(4):553–4, doi:10.1093/rheumatology/ken008View ArticleGoogle Scholar
  21. Gordon JK, Magro C, Lu T, Schneider R, Chiu A, Furman RR, Solomon G, Bass A, Erkan D (2009) Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery. HSS J 5(2):169–77, doi:10.1007/s11420-009-9123-xView ArticleGoogle Scholar
  22. Hoffmann A, Kirn E, Kuerten A, Sander C, Krueger GR, Ablashi DV (1991) Active human herpesvirus-6 (HHV-6) infection associated with Kikuchi-Fujimoto disease and systemic lupus erythematosus (SLE). Vivo 5(3):265–9Google Scholar
  23. Imamura M, Ueno H, Matsuura A, Kamiya H, Suzuki T, Kikuchi K, Onoe T (1982) An ultrastructural study of subacute necrotizing lymphadenitis. Am J Pathol 107(3):292–9Google Scholar
  24. Jimenez Saenz JM, Llorente Arenas EM, Fuentes Solsona F, de Miguel GF, Alvarez Alegret R (2001) Kikuchi-Fujimoto’s disease and the association with systemic lupus erythematosus. An Med Interna 18(8):429–31Google Scholar
  25. Kampitak T (2008) Fatal Kikuchi-Fujimoto disease associated with SLE and hemophagocytic syndrome: a case report. Clin Rheumatol 27(8):1073–5, doi:10.1007/s10067-008-0902-4View ArticleGoogle Scholar
  26. Kucukardali Y, Solmazgul E, Kunter E, Oncul O, Yildirim S, Kaplan M (2007) Kikuchi-Fujimoto Disease: analysis of 244 cases. Clin Rheumatol 26(1):50–4, doi:10.1007/s10067-006-0230-5View ArticleGoogle Scholar
  27. Leyral C, Camou F, Perlemoine C, Caubet O, Pellegrin JL, Viallard JF (2005) [Pathogenic links between Kikuchi’s disease and lupus: a report of three new cases]. Rev Med Interne 26(8):651–5, doi:10.1016/j.revmed.2005.03.018View ArticleGoogle Scholar
  28. Londhey VA, Buche AS, Kini SH, Rajadhyaksha GC (2010) Kikuchi fujimoto disease and systemic lupus erythematosus–a rare association. J Assoc Physicians India 58:642–3Google Scholar
  29. Mahajan T, Merriman RC, Stone MJ (2007) Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis): report of a case with other autoimmune manifestations. Proc (Bayl Univ Med Cent) 20(2):149–51Google Scholar
  30. Mootsikapun P, Sirijerachai J, Nanagara R (2002) Kikuchi-Fujimoto’s disease, histiocytic necrotizing lymphadenitis, mimicking systemic lupus erythematosus. J Med Assoc Thai 85(9):1037–41Google Scholar
  31. Ogata S, Bando Y, Saito N, Katsuoka K, Ishii M (2010) Kikuchi-Fujimoto disease developed into autoimmune disease: a report of two cases. Mod Rheumatol 20(3):301–5, doi:10.1007/s10165-009-0269-7View ArticleGoogle Scholar
  32. Pace-Asciak P, Black MA, Michel RP, Kost K (2008) Case Series: raising awareness about Kikuchi-Fujimoto disease among otolaryngologists: is it linked to systemic lupus erythematosus? J Otolaryngol Head Neck Surg 37(6):782–7Google Scholar
  33. Paradela S, Lorenzo J, Martinez-Gomez W, Yebra-Pimentel T, Valbuena L, Fonseca E (2008) Interface dermatitis in skin lesions of Kikuchi-Fujimoto’s disease: a histopathological marker of evolution into systemic lupus erythematosus? LUPUS 17(12):1127–35, doi:10.1177/0961203308092161View ArticleGoogle Scholar
  34. Patra A, Bhattacharya SK (2013) SLE developing in a follow-Up patient of Kikuchi’s disease: a rare disorder. J Clin Diagn Res 7(4):752–3, doi:10.7860/JCDR/2013/5017.2904Google Scholar
  35. Patra A, Bhattacharya SK (2014) SLE developing in a follow-up patient of Kikuchi’s Disease: a rare disorder. J Clin Diagn Res 7(4):752–3, doi:10.7860/JCDR/2013/5017.2904Google Scholar
  36. Prignano F, D’Erme AM, Zanieri F, Bonciani D, Lotti T (2012) Why is Kikuchi-Fujimoto disease misleading? Int J Dermatol 51(5):564–7, doi:10.1111/j.1365-4632.2011.05052.xView ArticleGoogle Scholar
  37. Quintas-Cardama A, Fraga M, Cozzi SN, Caparrini A, Maceiras F, Forteza J (2003) Fatal Kikuchi-Fujimoto disease: the lupus connection. Ann Hematol 82(3):186–8, doi:10.1007/s00277-003-0611-7Google Scholar
  38. Ruaro B, Sulli A, Alessandri E, Fraternali-Orcioni G, Cutolo M (2014) Kikuchi-Fujimoto’s disease associated with systemic lupus erythematous: difficult case report and literature review. LUPUS 23(9):939–44, doi:10.1177/0961203314530794View ArticleGoogle Scholar
  39. Sanpavat A, Wannakrairot P, Assanasen T (2006) Necrotizing non-granulomatous lymphadenitis: a clinicopathologic study of 40 Thai patients. Southeast Asian J Trop Med Public Health 37(3):563–70Google Scholar
  40. Santana A, Lessa B, Galrao L, Lima I, Santiago M (2005) Kikuchi-Fujimoto’s disease associated with systemic lupus erythematosus: case report and review of the literature. Clin Rheumatol 24(1):60–3, doi:10.1007/s10067-004-0923-6View ArticleGoogle Scholar
  41. Shusang V, Marelli L, Beynon H, Davies N, Patch D, Dhillon AP, Burroughs AK (2008) Autoimmune hepatitis associated with Kikuchi-Fujimoto’s disease. Eur J Gastroenterol Hepatol 20(1):79–82, doi:10.1097/MEG.0b013e32825a6a9eView ArticleGoogle Scholar
  42. Silver SG, Hong HC, Ting PT, Ball NJ (2004) Kikuchi-Fujimoto’s necrotizing lymphadenitis in association with discoid lupus erthematosus: a case report. J Cutan Med Surg 8(6):442–5, doi:10.1007/s10227-004-0119-3View ArticleGoogle Scholar
  43. Smith LW, Petri M (2013) Diffuse lymphadenopathy as the presenting manifestation of systemic lupus erythematosus. J Clin Rheumatol 19(7):397–9, doi:10.1097/RHU.0b013e3182a6a924View ArticleGoogle Scholar
  44. Sontheimer RD, Thomas JR, Gilliam JN (1979) Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 115(12):1409–15View ArticleGoogle Scholar
  45. Sopena B, Rivera A, Vazquez-Trinanes C, Fluiters E, Gonzalez-Carrero J, del Pozo M, Freire M, Martínez-Vázquez C (2012) Autoimmune manifestations of Kikuchi disease. Semin Arthritis Rheum 41(6):900–6, doi:10.1016/j.semarthrit.2011.11.001View ArticleGoogle Scholar
  46. Tanasescu C, Nitescu D, Staniceanu F, Ardeleanu C, Atanasiu C (2003) Kikuchi’s disease associated with systemic lupus erythematosus and autoimmune-like hepatitis. Rom J Intern Med 41(3):299–305Google Scholar
  47. Vassilakopoulos TP, Pangalis GA, Siakantaris MP, Levidou G, Yiakoumis X, Floudas C, Gribabis D, Bouros S, Metaxas I, Dimitriadou EM, Pantazi L, Tsoukala C, Korkolopoulou P, Andreopoulos A, Vaiopoulos G (2010) Kikuchi’s lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome. Rheumatol Int 30(7):925–32, doi:10.1007/s00296-009-1077-2View ArticleGoogle Scholar
  48. Wano Y, Ebata K, Masaki Y, Takeshita S, Ogawa N, Kim CG, Okada J, Saito H, Hirose Y, Tohyama T, Sugai S (2000) Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto’s disease) accompanied by hemophagocytosis and salivary gland swelling in a patient with systemic lupus erythematosus. Rinsho Ketsueki 41(1):54–60Google Scholar
  49. Yilmaz M, Camci C, Sari I, Okan V, Sevinc A, Onat AM, Buyukhatipoglu H (2006) Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto’s disease) mimicking systemic lupus erythematosus: a review of two cases. LUPUS 15(6):384–7View ArticleGoogle Scholar
  50. Zuo Y, Foshat M, Qian YW, Kelly B, Harper B, Karnath B (2012) A rare case of Kikuchi Fujimoto’s disease with subsequent development of systemic lupus erythematosus. Case Rep Rheumatol 2012:325062, doi:10.1155/2012/325062Google Scholar

Copyright

© Sharma and Rankin; licensee Springer. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.